Loading...

XML

Word

Printable

Contact Name:
Whitney Damson
Contact Email:
wdamson@ncqa.org
Contact Phone:
202 955 1732
Institution/Name:
National Committee for Quality Assurance
Solution:

Hide
Thank you for your question regarding 347v7, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. For patients not included in Populations 1 through 3, in instances where there are multiple ASCVD risk estimates, reporting entities should use the most recent ASCVD risk estimate relative to the encounter qualifying the patient for Population 4.

Show
Thank you for your question regarding 347v7, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. For patients not included in Populations 1 through 3, in instances where there are multiple ASCVD risk estimates, reporting entities should use the most recent ASCVD risk estimate relative to the encounter qualifying the patient for Population 4.
2024 Performance Period EC eCQMs:

CMS0347v7
Impact:
The ASCVD risk score can vary throughout the measurement period as there are many components to the calculation. For inclusion in population 4, should we use the first, the most recent, or any risk score >=20 in the measure year?